These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 28755539)

  • 1. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
    Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer.
    Li T; Chen X; Liu Y; Fan L; Lin L; Xu Y; Chen S; Shao J
    Eur J Pharm Sci; 2017 Jan; 96():456-463. PubMed ID: 27771513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
    Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
    Eur J Pharm Sci; 2018 Jan; 111():492-502. PubMed ID: 29107835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
    Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A smart pH-responsive nano-carrier as a drug delivery system for the targeted delivery of ursolic acid: suppresses cancer growth and metastasis by modulating P53/MMP-9/PTEN/CD44 mediated multiple signaling pathways.
    Jiang K; Chi T; Li T; Zheng G; Fan L; Liu Y; Chen X; Chen S; Jia L; Shao J
    Nanoscale; 2017 Jul; 9(27):9428-9439. PubMed ID: 28660943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A self-assembly nanodrug delivery system based on amphiphilic low generations of PAMAM dendrimers-ursolic acid conjugate modified by lactobionic acid for HCC targeting therapy.
    Shen Z; Li B; Liu Y; Zheng G; Guo Y; Zhao R; Jiang K; Fan L; Shao J
    Nanomedicine; 2018 Feb; 14(2):227-236. PubMed ID: 29128661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
    Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
    Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J; Liu Y; Meng L; Ji B; Yang D
    Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
    [No Abstract]   [Full Text] [Related]  

  • 12. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma.
    Yin X; Xiao Y; Han L; Zhang B; Wang T; Su Z; Zhang N
    AAPS PharmSciTech; 2018 Jul; 19(5):2133-2143. PubMed ID: 29714002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
    Yang S; Zhang B; Gong X; Wang T; Liu Y; Zhang N
    Int J Nanomedicine; 2016; 11():2329-43. PubMed ID: 27307733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
    Yao Y; Su Z; Liang Y; Zhang N
    Int J Nanomedicine; 2015; 10():6185-97. PubMed ID: 26491291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
    Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
    Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W; Zhu S; Cao J; Zhang L; Li W; Liu K; Zhong J; Shang C; Chen Y
    Oncol Res; 2017 Nov; 25(9):1543-1553. PubMed ID: 28276313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
    Zhang Y; Zhang B; Zhang A; Zhao Y; Zhao J; Liu J; Gao J; Fang D; Rao Z
    Clinics (Sao Paulo); 2012 Sep; 67(9):1093-9. PubMed ID: 23018309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.
    Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X
    Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
    Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
    J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
    Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
    Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.